Howard Capital Management Inc. Purchases 38 Shares of IDEXX Laboratories, Inc. $IDXX

Howard Capital Management Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.9% during the second quarter, Holdings Channel.com reports. The firm owned 2,035 shares of the company’s stock after buying an additional 38 shares during the quarter. Howard Capital Management Inc.’s holdings in IDEXX Laboratories were worth $1,091,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. Stratos Wealth Partners LTD. increased its position in IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company’s stock worth $564,000 after buying an additional 18 shares during the period. Red Spruce Capital LLC increased its position in IDEXX Laboratories by 1.1% during the second quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock worth $912,000 after acquiring an additional 19 shares during the period. Phoenix Financial Ltd. increased its position in IDEXX Laboratories by 1.7% during the second quarter. Phoenix Financial Ltd. now owns 1,181 shares of the company’s stock worth $633,000 after acquiring an additional 20 shares during the period. Rise Advisors LLC increased its position in IDEXX Laboratories by 3.9% during the second quarter. Rise Advisors LLC now owns 562 shares of the company’s stock worth $301,000 after acquiring an additional 21 shares during the period. Finally, Harbour Investments Inc. increased its position in IDEXX Laboratories by 27.3% during the second quarter. Harbour Investments Inc. now owns 98 shares of the company’s stock worth $53,000 after acquiring an additional 21 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. Piper Sandler reaffirmed a “neutral” rating and set a $700.00 target price (up from $510.00) on shares of IDEXX Laboratories in a report on Monday, August 11th. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a research note on Monday, August 4th. Leerink Partners raised their price objective on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, July 17th. Morgan Stanley raised their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the stock an “overweight” rating in a research note on Friday, August 15th. Finally, Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $656.50.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $634.36 on Wednesday. The company’s 50 day simple moving average is $638.55 and its 200 day simple moving average is $563.81. The stock has a market capitalization of $50.75 billion, a price-to-earnings ratio of 52.82, a price-to-earnings-growth ratio of 4.19 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter last year, the company posted $2.44 EPS. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director owned 262 shares in the company, valued at $169,600.46. The trade was a 89.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total value of $18,491,734.80. Following the completion of the transaction, the chief executive officer owned 83,311 shares in the company, valued at approximately $52,650,885.78. This represents a 25.99% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 54,057 shares of company stock valued at $34,293,468. Company insiders own 0.98% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.